NSD1 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NSD1 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].